Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said.
The University of Birmingham spin-out is working to advance cancer treatment